Lead Auditor Training
ISO 29993:2017 Certification
TNV encourage to adopt and implement
latest available standards ISO 9001:2015 & ISO 14001:2015, hence no
application shall be accepted after 01st Jan. 2017 for ISO 9001:2008 & ISO
14001-2004 standard, earlier this date was 01st Sept. 2017. Existing client may
continue using their certification status till the validity of the standards
i.e. 15th Sept. 2018
TNV's is not anymore Accredited by JAS-ANZ (Joint Accreditation System of Australia
& New Zeland) for QMS, EMS, OHSAS and FSMS with effect from 30th January 2017.
Accordingly all Accredited certificate issued by TNV for QMS, EMS, OHSAS and
FSMS with JAS-ANZ logo is recalled as use of logo of JAS-ANZ with the name of TNV is unauthorised and not fair and all such certificate have been removed from
JAS-ANZ portal by 30th April 2017. TNV advise our client to contact us for surrender of certificate. if clietn dont want to continue with TNV, they may choose any Certifictaion body of its choice.
TNV is certified by Exemplar Global for Lead Auditor Course of ISO 9001
TNV Have aproval for location Nepal, Kuwait, Bangladesh and United State of America as a additional location in Financial year 2013-14, Further TNV have started in Taiwan, Qatar, Maldives, Egypt, Vietnam, South Africa and Brazil.. Board of the Director have considered aspects for the overseas operation and expanding to many countires; we invite inquiries for Business Association or franchises for ISO Certification Services.
TNV's Accreditation of JAS-ANZ (Joint Accreditation System of Australia & New Zeland) for QMS, EMS, OHSAS and FSMS is revked by 30th January 2017. Accordingly all Accredited certificate issued by TNV for QMS, EMS, OHSAS and FSMS shall stand cancelled and all the certificate shall be removed from JAS-ANZ portal by 30th April 2017. If client is looking from JAS-ANZ accredited certificate, client may please take transfer of the certificate on time to any JAS-ANZ accredited CAB or any other Certification body of thier choice.
Managing Director, TNV Mr. Pragyesh Singh Visited South Africa our Marketing office at Cape Town
Managing Director, TNV Mr. Pragyesh Singh is visiting Indonesia for signing contract for starting operation there.
TNV's Lead Auditor Training Program for ISO 14001, OHSAS 18001, ISO 22000, ISO 27001, ISO 13485, ISO 28000, ISO/TS 16949 planned in August 2015, September 2015, October 2015, November 2015, and December 2015. Exemplar Global certified Course
Managing Director, TNV Mr. Pragyesh Singh Visiting Egypt, UAE and Taiwan for Annual Review of Overseas office in June.
TNV’s Logo is the Registered Trademark of the TNV vide Trade Mark Number 2420078 Dated 31st October 2012 J. No. 1620 at Sl. No. 1183020 in Class 35 for Business and Risk Management, Administration and Auditing, Management System Certification Services, Product Certification Services, Compliance & Other Certification Services, Any misuse of the logo shall be governed as per provisions of Trade Marks Act 1999.
The impetus for the development of ISO 45001 came from the British Standards Institute (BSI), which proposed to ISO in 2013 that OHSAS 18001 be considered as the basis for an international standard. ISO agreed and established a committee to oversee its development. As the proposers, BSI took on the role of Secretariat to the new committee (ISO PC 283). The first meeting of ISO PC 283 took place in London in October 2013, where key decisions were made, for example, that the standard would contain the requirements and include interpretative guidance as an annex. The WG was established and further divided into Task Groups (TGs) to separate the workload into manageable sections, so that each TG could focus on one or more clauses of the draft standard
With effect from 30th Jan 2017, JAS-ANZ Accreditation have been revoked as TNV could not inform JAS-ANZ withdral informaiton of the DAC. an appleal in this respect is pending with JAS-ANZ, TNV have not recieved any communication in respect of appeal submitted against cancellation of the accreditaiton of the TNV. Informaiton of the same have been filed to IAF in this reference to ensure execution of the appeal submitted.
Good manufacturing practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. The main risks are: unexpected contamination of products, causing damage to health or even death; incorrect labels on containers, which could mean that patients receive the wrong medicine; insufficient or too much active ingredient, resulting in ineffective treatment or adverse effects. GMP covers all aspects of production; from the starting materials, premises and equipment to the training and personal hygiene of staff. Detailed, written procedures are essential for each process that could affect the quality of the finished product. There must be systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process - every time a product is made. WHO has established detailed guidelines for good manufacturing practice. Many countries have formulated their own requirements for GMP based on WHO GMP. Others have harmonized their requirements, for example in the Association of South-East Asian Nations (ASEAN), in the European Union and through the Pharmaceutical Inspection Convention.
Yes. Good quality must be built in during the manufacturing process; it cannot be tested into the product afterwards. GMP prevents errors that cannot be eliminated through quality control of the finished product. Without GMP it is impossible to be sure that every unit of a medicine is of the same quality as the units of medicine tested in the laboratory
Yes. Making poor quality products does not save money. In the long run, it is more expensive finding mistakes after they have been made than preventing them in the first place. GMP is designed to ensure that mistakes do not occur. Implementation of GMP is an investment in good quality medicines. This will improve the health of the individual patient and the community, as well as benefiting the pharmaceutical industry and health professionals. Making and distributing poor quality medicines leads to loss of credibility for everyone: both public and private health care and the manufacturer.
WHO GMP guidelines are available online. If you require more information, please contact the WHO representative in your country, your WHO regional office or WHO headquarters in Geneva.
CE Marking Certification
CE Notified Body
CMMi Level 2
CMMi Level 3
CMMi Level 4
CMMi Level 5
Code of Integrity
Internal Auditor Training
ISO 13485 Certification
ISO Application Process
Key Elements of BCMS
Low Voltage CE
Use of Marks
Certification Process |
Regulation, Complaints & Appeal |
Certification Benefits |
Sample Certificate |
GMP Certification |
Accreditation Statement |
| Marketing Offices
ISO 13485 Certification